SFG
CORT icon

Steward Financial Group’s Corcept Therapeutics CORT Stock Holding History

Steward Financial Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$2K Buy
+80
New +$2.31K ﹤0.01% 947
2022
Q3 		– Sell
-45
Closed -$1K – 347
2022
Q2 		$1K Buy
+45
New +$980 ﹤0.01% 702

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

Steward Financial Group's CORT Position: Q3 2023 in Review

Steward Financial Group opened a new position in Corcept Therapeutics (CORT) in Q3 2023: 80 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #947 among its holdings. This is a return to the name: Steward Financial Group previously reported a position in CORT as recently as Q2 2022.

Steward Financial Group first reported a position in CORT in Q2 2022 and has held it in 2 quarters since. 246 funds tracked by Wall St. Rank hold CORT as of Q3 2023.

  • Steward Financial Group held 80 shares of Corcept Therapeutics worth $2K as of Q3 2023.
  • Corcept Therapeutics was a new Steward Financial Group position in Q3 2023.
  • Corcept Therapeutics made up ﹤0.01% of Steward Financial Group's portfolio in Q3 2023, its #947 holding.
  • Steward Financial Group first reported a position in Corcept Therapeutics in Q2 2022 and has held it in 2 quarters since.
  • 246 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2023.

Based on Steward Financial Group's 13F filing for Q3 2023, filed 23 Oct 2023.